Join Dr. Richter as he discusses the difference between smoldering myeloma and symptomatic multiple myeloma, and emerging criteria to classify and treat the former.

Join Dr. Giralt as he explains whether or not you should wait for the development of CRAB before initiating therapy for your multiple myeloma patients.

Join Dr. Landgren as he discusses the relative value of multicolor flow cytometry in an assessment for minimal residual disease (MRD) in multiple myeloma, compared to allele-specific PCR.

Join Dr. Orlowski as he discusses how to select between carfilzomib and ixazomib as a proteosome inhibitor, especially in the relapsed or refractory setting.

Join Dr. Richter as he explains the clinical significance of minimal residual disease (MRD) testing in multiple myeloma.

Join Dr. Orlowski as he explains how he decides between using a doublet or a triplet salvage regimen for his multiple myeloma patients.

Join Dr. Lonial as he explains how the new International Myeloma Working Group definition of active multiple myeloma will affect clinical practice.

Join Dr. Landgren as he explains how immunotherapeutic agents and monoclonal antibodies fit into the real-world treatment of patients with multiple myeloma.

Join Dr. Giralt as he explains the new recommended baseline workup tests for multiple myeloma.

Dr. Lonial discusses how to determine which patients will benefit the most from treatment with daratumumab and elotuzumab.